Karl Kuhn, MD
Pulmonary Disease · Nashville, TNNPI 1003876236
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,325 of the $105,764 with a category attached, or 75.9%. Lilly USA, LLC accounts for 94.8% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $101,592, more than ten times the $585 reported in 2019. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $286.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$100K
- AstraZeneca$1K
- GSK$681
- Actelion Pharmaceuticals US, Inc.$458
- Boehringer Ingelheim$330
- Insmed, Inc.$268
- plus $2K from 32 others
What the payments were for
- Consulting fees$4,7254%
- Speaking & faculty fees$80,32576%
- Travel & lodging$13,83313%
- Food & beverage$6,6776%
- Education$2030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 153 | $100,300 |
| AstraZeneca | 46 | $1,326 |
| GSK | 39 | $681 |
| Actelion Pharmaceuticals US, Inc. | 15 | $458 |
| Boehringer Ingelheim | 14 | $330 |
| Insmed, Inc. | 13 | $268 |
| Inspire Medical Systems, Inc. | 6 | $268 |
| Amgen | 6 | $231 |
| Philips North America LLC | 5 | $183 |
| Jazz Pharmaceuticals Inc. | 6 | $166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $152 |
| Baxter Healthcare | 4 | $137 |
| Regeneron Healthcare Solutions, Inc. | 6 | $129 |
| Advanced Respiratory, Inc | 6 | $107 |
| Pfizer | 5 | $105 |
| CSL Behring | 5 | $99 |
| United Therapeutics Corporation | 4 | $97 |
| Sanofi | 3 | $89 |
| Mylan Specialty L.p. | 4 | $62 |
| Johnson & Johnson | 2 | $61 |
| Verona Pharma, Inc. | 2 | $56 |
| Harmony Biosciences LLC | 2 | $53 |
| Electromed, Inc. | 3 | $46 |
| Vifor Pharma, Inc. | 1 | $36 |
| Fisher & Paykel Healthcare Inc | 1 | $35 |
| 3b Medical, Inc. | 1 | $30 |
| Tactile Systems Technology Inc | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $29 |
| Grifols USA, LLC | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Viatris Specialty LLC | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,764 in reported general payments places this provider in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $324,155 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 407 | $315,257 |
| Pirfenidone | 12 | $69,882 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $66,004 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $46,445 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 90 | $16,186 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 283 | $8,052 |
| XareltoRivaroxaban | 11 | $7,834 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,391 |
| Wixela InhubFluticasone Propion/Salmeterol | 42 | $6,644 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,546 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,715 |
| AlvescoCiclesonide | 12 | $3,751 |
| Azelastine Hcl | 79 | $2,697 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $681 | $386,808564 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $330 | $331,54536 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,326 | $51,16087 claims |
| Johnson & JohnsonXarelto | $61 | $7,83411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Lisa LancasterNashville$519K
- Otis RickmanNashville$392K
- Susan GarwoodNashville$343K
- Joao DeandradeNashville$245K
- Anna HemnesNashville$183K
- Bryan HayNashville$126K
- Fabien MaldonadoNashville$83K
- Margaret SalisburyNashville$53K
- Victor KhaNashville$44K
- Jennifer DukeNashville$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.